Varicella zoster virus the ACIP recommended a second dose of vaccine before school entry to ensure the maintenance of high levels of varicella immunity. In 2006, the United States Food and Drug Administration approved Zostavax for the prevention of shingles. Zostavax is a more concentrated formulation of the Varivax vaccine, designed to elicit an immune response in older adults whose immunity to VZV wanes with advancing age. A systematic review by the Cochrane Library shows that Zostavax reduces the incidence of shingles by almost 50%. Shingrix is a "V. zoster" vaccine developed by GlaxoSmithKline which was approved in the United States by the
Reactive airway disease Reactive airway disease Reactive airway disease is a general term used by many physicians to label patients with symptoms similar to those of asthma. It is most commonly used when a physician is hesitant about formally diagnosing a patient with asthma, which is most prevalent in the pediatric setting for a variety of reasons. While some physicians may use RAD and asthma synonymously, this causes controversy, since RAD can not be used as a real diagnosis for physicians. An exact definition of the condition does not exist. Individuals that are typically labeled as having reactive airway disease, or RAD, generally